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ABSTRACT
The Instrumentation Laboratory's MicroCentrifugal
Analyzer (MCA) was evaluated for precision, linearity and
accuracy for albumin, alanine transaminase (ALT), aspartate
transaminase (AST) , alkaline phosphatase, creatine kinase
(CK), cerebrospinal fluid (CSF) total protein, cholesterol,
glucose, gamma-glutamyl transpeptidase (GGT), lactic
dehydrogenase (LDH) , phosphorous, total protein, and
triglyceride. Within-run, within-day, day-to-day, and
total precision was comparable to or exceeded
manufacturer's claims and was comparable to the precision
in existing in-house tests. A comparison of methods for
the MicroCentrifugal Analyzer with those used on the
Technicon SMA 12/60, the Abbott ABA-100 and the Kodak
Ektachem 400 showed very good correlation with minimal
random error -
As a result of this study, the MicroCentrifugal Analyzer
was implemented in this laboratory as a replacement
instrument for the ABA 100 and as a backup instrument for
the SMA 12/60 and Ektachem 400. A new activated creatine
kinase kit was adopted and the existing cerebrospinal fluid
total protein biuret method was replaced with an automated
Coomassie blue method.
INTRODUCTION
Centrifugal analyzers were developed to allow for more
rapid chemical assays as well as reactions in parallel
rather than continuous flow*. Once centrifugal analyzers
were developed, miniaturization of the final prototypes
became a new focus of development. The Instrumentation
Laboratory's (ID Micro Centrifugal Analyzer, hereafter
referred to as the MCA, is such an instrument. The MCA is
a sophisticated multicuvet spectrophotometer with on-line
data handling capabilities. It requires small amounts of
sample per assay and allows parallel analysis by initiating
reactions in each cuvet simultaneously2. This means that
identical conditions of time, temperature, and reactant
composition exist for standards, control material and
patient samples. A separate loader serves to pipet samples
and reagents into a multi-cuvet rotor, keeping reactants
separated by a dam until mixing commences in the analyzer -
The evaluation of the MCA by this laboratory was
designed to generate data for three types of analyses,
colorimetric end-point reactions, fixed end-point kinetic
reactions, and enzymatic rate reactions. Sample and
reagent loading and analysis parameters provided by IL were
designed specifically for IL reagent kits and a reaction
temperature of 30C. Since this laboratory prefers a 37C
reaction
temperature3 and wished to use reagent kits
currently in use, each method evaluated was adapted to 37C
and existing reagent kits. This meant that timing studies
were necessary to make sure that enzymatic reactions were
read during the linear portion of the curve and
colorimetric reactions had reached end-point. For creatine
kinase (CK) , a new kit was evaluated at a reaction
temperature of 37QC.
For this study, 13 chemistry tests were adapted to the
MCA and examined for precision, linearity and accuracy -
Colorimetric tests included glucose, total protein,
albumin, cholesterol, serum and urine phosphorous and
cerebrospinal fluid protein. The uric acid kit in use in
the laboratory proved to have a non-linear reaction curve
that could not be adapted to the MCA's algorithm. A
literature search indicated there would continue to be
problems with uric acid analyis on a centrifugal analyzer4.
Since another backup method was available for uric acid,
and since a need arose for an automated spinal fluid
protein method using very small sample volume, evaluation
for CSF protein was substituted for uric acid. Tri
glycerides represented the fixed-kinetic reaction and
enzymatic methods adapted were for aspartate transaminase
(AST) , alanine transaminase (ALT) . alkaline phosphatase,
CK, gamma- glutamyl transpeptidase (GGT) and lactic
dehydrogenase (LD) .
Precision was determined using a ten-day modification of
the National Committee for Clinical Laboratory Standards
(NCCLS) protocol5 and within-run, run-to-run, day-to-day,
and total precision were calculated using nested analysis
of variance (ANOVA).S Comparison was made to the
manufacturer's stated precision data and the instrument and
methodology the MCA was intended to replace.
Since this instrument was intended to be used partly to
analyze serum with analyte levels greater than the
linearity of the SMA 12/60, linearities needed to be
determined for each method in order to set upper limits.
Accuracy studies involved comparison of patient results
obtained from the MCA with methods already verified and
accepted as precise, linear, and accurate. A linear
regression analysis was used to compare results with the
MCA data as the dependent variable Y and the comparative
method as the independent variable X. The regression
equation incorporating slope and intercept, the correlation
coefficient, and the random error around the mean, sy.x
were calculated for each method.
A reference range study was carried out to determine
whether the established reference ranges were valid for the
new testing system. Specimens were obtained from routine
blood donations to the American Red Cross.
MATERIALS AND METHODS
Reagent kits presently in use in the laboratory were
adapted to the MCA as described in the instrument manual 7 .
For CK analysis an activated kit was adapted, and for CSF
total protein a Pierce microprotein method was adapted to
the MCA. The instrument evaluated was the Instrumentation
Laboratory's Micro Centrifugal Analyzer, Instrumentation
Laboratory, Inc., 113 Hartwell Ave., Lexington, MA, 02173.
All tests were set up at 37 C.
Enzymatic methods
The general theory behind the rate reaction involves
allowing the reaction to come to a steady state, taking
absorbance readings at timed intervals during the linear
phase of the reaction, and calculating the results based on
an enzyme factor generated during the method adaptation.
The enzyme factor takes into consideration the volumes of
sample and substrate used, the molar absorptivity of the
test's particular wavelength, and cuvette light path
length. The enzyme factor (EF) converts the change in
absorbance per minute into international enzyme units per
liter (IU/L). The general formula for enzyme factor
calculation is:8
EF = Vr x 1.x 1 x 106
Vs E PL
where
Vr = total reaction volume in ml
Vs = sample volume in ml
E = molar absorptivity for reaction species
(at 340 nm, NADH = 6.22 x IO3, used for AST, ALT, CK,
and LD
at 405 nm, PNP = 18.8 x IO3. used for alkaline
phosphatase
at 405 nm, p-nitroanilide = 9.9 x 103, used for GGT)
The linearity of enzyme kinetics is related to the
activity of the enzyme and the concentration of substrate
in the total reaction volume. Sufficient substrate should
be available to ensure zero order kinetics, i. e., the
reaction rate should be constant and directly proportional
to enzyme activity. Therefore, once a method was adapted,
substrate depletion studies were also performed according
to the operator manual's protocol. 9
For alkaline phosphatase, the Worthington diagnostic kit
was adapted . It is based on the method of Bowers and
McComb, where alkaline phosphatase hydrolyzes p-nitro-
phenylphosphate (PNP) to p-nitrophenol and phosphate.
P-nitrophenol is yellow in alkaline solution and its
increase, measured at 405 nm, is directly proportional to
the alkaline phoshatase activity.10
For ALT, the Dow ALT(GPT)-UV, PLP-activated Kit was
adapted to the MCA. This assay is a modification of Henry,
which allows measurement of the isoenzyme content of
hepatic tissue in accordance with the recommendation of the
German Society of Clinical Chemistry and the International
Federation of Clinical Chemistry.il L-alanine and 2-
oxoglutarate undergo transamination in the presence of
holoenzyme ALT. L-alanine is converted to pyruvate which
reacts with NADH in the presence of LDH to produce lactate
and NAD*. The rate of decrease in NADH concentration is
measured at 340 nm and is proportional to the ALT activity.
AST testing utilized the Worthington Statzyme GOT kit
based on the method of Henry, Amador and Wacker, modified
by Worthington^2 to include the use of oxamic acid to
eliminate interference from serum pyruvate. 2-oxoglutarate
and L-aspartate in the presence of AST form glutamate and
oxaloacetate. Oxaloacetate plus NADH catalyzed by excess
malate dehydrogenase forms malate and NAD. The oxidation
of NADH to NAD is measured by decreasing absorbance at 340
nm and is proportional to the AST activity -
The CK kit in use was replaced by one which included
thiol compounds to reactivate creatine kinase. CK is very
unstable due to the oxidation of the sulfhydryl groups in
the active site of the enzyme. N-acetyl-L-cysteine (NAC)
is included in the test system for reactivation of CK. The
methodology is based on
Szasz1-3
. AMP and adenosine-5' -
pentaphosphate are added to inhibit adenylate kinase
activity. Creatine phosphate and ADP is catalyzed by CK to
form creatine and ATP- ATP plus glucose in the presence of
hexokinase forms ADP and glucose-6-phosphate(G-6-P) . G-6-P
and NAD in the presence of G-6-P dehydrogenase forms 6-
phosphogluconate and NADH. The formation of NADH proceeds
at the same rate as the formation of creatine in equimolar
amounts and can be determined by the increase in absorbance
at 340 nm, which is directly proportional to the CK
activity.
GGT was measured with the Worthington Statzyme GGTP
reagent kit based on the method of Szasz with modification
by Worthington.14 The modification includes glutamate at
optimal concentration in the reaction system to eliminate
any variation that free glutamate in serum may cause in the
measured enzyme activity. GGT transfers the gamma-glutamyl
group from the substrate gamma-glutamyl-p-nitroanilide to
glycylglycine, yielding free p-nitroaniline, which absorbs
at 405 nm, and gamma-glutamylglycylglycine. Enzyme
activity is proportional to the increase in absorbance.
During the evaluation, a problem with precipitate formation
in the GGT reagent was resolved by a modification of
reagent preparation that included heating of the reagent to
ensure proper dissolution. This led to better precision
for this method than existed previously.
The Worthington Statzyme LDH (L-P) reagent kit was used
to evaluate LDH. The lactate to pyruvate method of
Wacker15 is the method of choice because of its greater
linearity, better proportionality to amount of enzyme and
better stability of reagents than methods employing the
pyruvate to lactate reaction. LDH catalyzes the conversion
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of lactate to pyruvate and NAD to NADH. LDH activity is
directly proportional to the increase in absorbance of NADH
at 340 nm .
The fixed kinetic rate reaction for triglyceride is also
based on a factor calculation, but unlike the enzyme factor
it also includes the molecular weight of the substrate.
Thus, this factor is referred to as a substrate factor and
is used to convert the change in absorbance into units of
concentration :^
Substrate Factor = MW x 100 x Vr_ x 1_ x 1
Vs E PL
where
MW = molecular weight of substrate
Vr = total reaction volume in ml
Vs = sample volume in ml
E = molar absorptivity of reaction species
PL = pathlength of cuvette in cm
The Abbott a-gent triglyceride kit was adapted to the
MCA. Triglycerides are hydrolyzed enzymatically by a
lipase and the free glycerol formed is determined
enzymatically by the disappearance of NADH at 340 nm. This
stoichiometric measure of the glycerol present is related
to the triglyceride content of the sample.17
Colorimetric methods
Colorimetric reactions were done either as end-point or
bichromatically depending on the need to blank out the
color due to reagent. Calculation is based on comparison
with a standard delta absorbance:18
EStd. ] x A A Sample = [Sample]
A A Std.
where
[Std. J = concentration of standard
^ A = absorbance change
[Sample] = concentration of sample
Pierce SpecTru BCG Albumin reagent supplied by Lancer
Chemistries was set up as a bichromatic procedure. This is
a dye-binding method using bromcresol green with the
addition of a surfactant to the reagent to prevent
precipitation of the albumin-bromcresol green adduct1^-
The colored product is read bichromatically at 690 nm for
the blank and 620 nm for the test and compared to a
standard of known concentration. The parameters given were
modified to include the correct blank and test filters and
an interval time (the time necessary to change the filters)
of 20 rather than 15 seconds as recommended by the
instrument manual.
Cholesterol was done bichromatically using the Abbott
a-gent kit. Cholesterol esters in serum are hydrolyzed to
free cholesterol by cholesterol ester hydrolase. The free
cholesterol produced is oxidized by cholesterol oxidase to
cholest-4-en-3-one with simultaneous production of hydrogen
peroxide, which oxidatively couples with 4-aminoantipyrine
and phenol in the presence of peroxidase to yield a
quinoneimine dye with an absorption maximum at 500 nm. The
10
amount of color produced is directly proportional to the
cholesterol content.20
Glucose methodology employed the Abbott Glucose-UV kit
wherein glucose in the sample is phosphorylated by
hexokinase and excess ATP in the presence of Mg++ to
glucose-6-phosphate (G6P) . G6P is oxidized in the presence
of NAD by glucose-6-phosphate dehydrogenase to 6 phospo-
gluconate. The reduction of NAD to NADH is measured at 340
nm and related to the amount of glucose present21 .
Phosporous was adapted to the MCA using the SmithKline
reagent kit. This is a bichromatic procedure in which
molybdate reacts with phosphate in acidic solution to form
phosphomolybdate which is then catalyzed by cupric ion to
form molybdenum blue. The color formation at 690 nm is
directly related to the amount of phosphorous present.22
Total protein utilized the bichromatic a-gent Abbott kit
and the biuret reaction. Polypeptides containing at least
two peptide bonds react with biuret reagent forming a
complex between cupric ion and protein nitrogen in an
alkaline medium. The color is read at 550 nm and is
directly proportional to the amount of protein present.23
For CSF total protein, the existing manual biuret method
with in-house reagent preparation was adapted to the MCA at
the same time that the Lancer Microprotein RapidStat kit
employing Coomassie blue was evaluated. The Pierce
Micro-
Protein kit is a modification of the Bradford Coomassie
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Brilliant Blue method.24 The modification includes the
addition of surfactants designed to equalize the different
reactivities of albumin and globulin which had been a
problem with the Coomassie blue procedure in the past.25
Coomassie brilliant blue combines with the various proteins
in spinal fluid to form a dye-protein complex which is
steel gray in color and measured at 610 nm.
Experimental Protocols
Time studies. A time study evaluation for each chem
istry method adapted to the MCA was performed according to
MCA protocol2^. Water, controls, and samples repre
sentative of the expected range of concentration were
evaluated. For end-point determinations, the final
reaction time selected represented that time when samples,
controls and standards had reached equilibrium. Figure 1 is
an example of an end-point time study. The triglyceride
fixed-kinetic time study was very much like an end-point
reaction since enzymatic hydrolysis was completed before
the final absorbance was measured. For rate reactions,
dilutions of a sample of high activity were evaluated to
determine the time when zero order kinetics occur. The
time studies were especially important for enzymatic
methods because they were adapted to 37 C, which meant
that the reaction would attain zero order kinetics faster
at this higher temperature than at the 30 C recommended by
the manufacturer- Figure 2 is an example of an enzyme time
12
Figure 1. Example of an End-point time study
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GLUCOSE TIME STUDY
0.9000 _
0.8000 "
0.7000
160 sec.
SA + 500 mg/dl
mixed 1 : 1
500 mg/dl
SA control
400 mg/dl
300 mg/dl
SN control
0.0000
Figure 2. Example of an Enzyme time study
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AST time study
0.800 _
0.700
o
c
CO
D
ly
O
m
Q
0.600
0.500 '
0.400 -
0.300 -
0.200 -
0.100 -
Suggest 60 sec. delay, 20 sec. interval for absorbance reads
study. For enzymatic methods, substrate depletion studies
were also conducted according to MCA protocol. The purpose
was to flag samples with very high sample activity so that
in use an operator would be able to estimate the degree of
dilution necessary from the absorbance data and save time
on re-analysis. Figure 3 is an example of a substrate
depletion study.
Precision study. Two runs a day with four hours between
runs was completed for a period of 10 days. The 10-day
protocol consisted of two five day periods with a two day
interruption to simulate weekend downtime. Each run
consisted of five replicate aliquots of lyophylized,
commercial control material at three levels of
concentration. Within-run, run-to-run, day-to-day, and
total precison were calculated and compared to expected
precision values claimed by the manufacturer.
Linearity study. Enzyme linearity studies were done by
using a pool of human serum with very high activity levels
of the enzyme being evaluated. Human serum rather than
control material was used so that the linearity curve
represented the same reaction matrix as the testing system.
Dilutions ranged from 5 to 100 * of the pool, with 5 a
representing a 1:20 dilution and 100?s representing an
undiluted aliquot of the pool. The per cent activity was
plotted against the delta absorbance. From the linearity
graph, the delta absorbance of the highest point of
15
Figure 3. Example of a Substrate depletion study
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LDH Substrate Depletion Study
0.560
0.^20
o.4eo
0.4J0
0.400
0.360
0.320
0.280
0.240
0.200
^ Depletion at A = 0.3740
Beginning A = 0.2600
Maximum^ = 0.1140
Incubate ah
20 ^0 60 80
Time, sec.
100 120 140
linearity was then determined and by applying the
appropriate enzyme factor, a unit value was calculated for
the particular enzyme in question. Figure 4 is an example
of an enzyme linearity study -
For all other tests, linearity studies also utilized a
pool of human serum which by another method had been de
termined to have a high concentration of the analyte in
question. Again, 5 to 100 % dilutions were made and a
linearity curve was plotted using the absorbance readings
versus the per cent concentration. Figure 5 is an example
of an end-point linearity study. For the CSF total protein
method, high protein content spinal fluid was pooled which
was then used for 5 to 100 per cent dilutions. All
dilutions were made with 0.9 % saline.
Accuracy study. Comparison analysis between the MCA
methodologies and the instruments and methods cited below
were completed as soon as the samples had been analyzed on
the primary instrument. The samples consisted of freshly
drawn patient sera that were obtained as soon as their
analysis was completed and then analyzed on the MCA. The
comparison instruments were calibrated and operated
according the laboratory's standard protocol. The
comparison study was conducted for a period of ten days
with two runs per day. 100 samples total was the analysis
goal, but for some tests it was not possible to obtain 100
samples over that time period. Instruments used in the
17
Figure 4. Example of an enzyme linearity study
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ALKALINE PHOSPHATASE Linearity Study
0.10
0.09
0.08
0.07
0.06
0.05
<!
0.04
0.03
0.02
0.01
0.08/20 sec.
0.24/min.
x 2954 (EF)
= 709 IU/1
40 50 60
Dilution, %
Figure 5. Example of an end-point linearity study
19
Cholesterol Linearity Study
0.700
0.600
0.500
0.400
0.300
0.200
0.100
0
I f 1
'4- 0.6 x 300 mg/dl
0.24
= 750 mg/dl
(Kit suggests 550 mg/dl)
r i l l l L
10 20 30 40 50 60 70 80 90 100
Dilution, %
comparison study were the SMA 12/60 (Technicon Instrument
Corp., Tarrytown, N.Y. 10591), the Ektachem 400 (Eastman
Kodak Co., Rochester, NY), and the ABA-100 (Abbott
Laboratories, North Chicago, IL 60064).
The SMA 12/60 tests were all Technicon procedures. For
most tests the same procedures that were in use for the
ABA-100 were adapted to the MCA. The CK method on the ABA-
100 utilized the Worthington STATZYME CPK REAGENT
(Worthington Diagnostic Systems, Freehold, NJ 07728), an
unactivated method analyzed at 37C. CSF total protein
concentrations were compared to the in-house biuret method.
Triglycerides were compared to the Ektachem 400 procedure
as well as the ABA-100.
Interference Study. The effect of lipemia on the total
protein method was studied to verify the claim that visible
lipemia does not affect TP results over the range of
linearity (12 mg/dl). Lipemic and non-lipemic serum
samples were analyzed separately, then mixed 1:1 and
analyzed again. The theoretical calculated TP value was
then compared to the actual measured result. The mixed
samples were also analyzed for triglyceride and
cholesterol .
RESULTS AND DISCUSSION
Precision study Tables I, II, and III are a summary of
the within run, within day (run-to-run), day-to-day and
total precision results obtained. The total coefficient of
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variation (CV) is the sum of of the within run, within day
and day-to-day precision data. Where available, comparison
was made to the precision data supplied by the manu
facturer, which usually included within run and day-to-day
precision. Precision was also compared to the precision of
the existing methods. As can be seen from the tables, total
precision data was rarely supplied by either IL or the kit
manufacturers. In general, poorest precision occurred at
the lowest levels of analyte. For enzymes, the laboratory
in the past utilized an overall total precison of 10 X or
less over all levels of concentration as a rule-of -thumb
for acceptable variation. Typically, manufacturer's claims
were based on a much smaller number of values than in this
study and probably were optimistically lower over the
course of the manufacturer's study than in actual use. The
precision values obtained in this study were as good or
better than these claims. For enzymes, the low concen
trations of analyte were not represented in the manu
facturer's claims. All of the enzymes at their highest
respective activity levels had much better precision than
claimed by the manufacturer- In fact, it was found that the
enzymes total precision was better than the manufacturers
day-to-day claims. For colorimeteric procedures, again the
precision obtained matched or bettered that of the manu
facturer. For urine phosphorous, the precision of 2.44 was
better than that in the method it was designed to replace,
21
Table I. Statistical Analysis of Precision Data for Enzymes
II
Analyte II
II '
. Within
Mean 8 run
a
i
Within
day
IDay-to-day
i 8
Total
KIU/L) 1 S CV,* i S CV,* a s cv,*
a
a S CV,*
Alkaline I
phosphatase
i
II
(12/60 total
Manufacturer
i df =
i
41 11.81
78 11.92
169 12.29
CV: 3.64*
's CV:l.9 -
=80 i
i
4.42 II
2.45 a
1.35 a
@ x=89,
- 2.2 1
df=10
0.90 2.19
2.69 3.44
2.88 1.70
, 2.57* 0 x=
2.6 -2.7
1 df=9
11.85 4.51
10.80 1.02
11.66 0.98
307)
12.8 - 3.3
a
i
12
83
83
a
a
df=99
.68 6.53
.35 4.28
.96 2.34
3.9
ALT I 1 df==72 a df=9 8 df=8 u df=89
II I i 1 a
1 16 10.46 2.82 a 0.33 2.02 10.22 1.35 ao .57 3.52
1 29 10.65 2.19 i 0.39 1.31 B0. 41 1.38 80 .81 2.74
8 89 10.90 1.01 a 0.93 1.05 10.63 0.72 11 .33 1.50
8 8 a I 8
Manufacturer -s cv : 3.3 a I 4.6 8 8.0
AST 1 1 df =80 i df=10 1 df =9 a df=99
i i i 1 8
1 16 10.79 4.87 1 0.77 4.78 11.08 6.67 ai .51 9.29
i 29 10.88 3.07 I 0.77 2.68 10.56 1.96 ii .28 4.45
1 86 11.26 1.47 1 1.75 2.04 11.53 1.78 12 .59 3.01
(12/60 total CV: 17.72* @ x= 19, 3.18* @ x=183) I
Manufacturer 's cv: 2.8 - 4.2 I 2.0 - 4.7 85.9 - 10.0 I
C K I
I
I
1 df=80 i
a
a
df=10 8 df=9
8
10.78 3.79
a
i
8
df=99
21 10.70 3.42 1.83 8.90 2.07 10.04
1 44 10.93 2.11 e 1.43 3.25 11.89 4.30 8 2.47 5.61
1 271 14.02 1.49 112.20 4.51 8 112.31 4.55
a 1 i 1 8
Manufacturer 's cv: 2.1 - 9.31 87.3 - 14.1 1
GGT I I df=72
a
a
a
a
df=9 1 df=8
8
80.33 1.58
1
8
8
df =89
i 1
21 10.77 3.66 0.59 2.80 0.97 4.60
j 40 10.76 1.90 a 0.69 1.72 10.40 1.00 8 1.04 2.62
8
1
Manufacturer
128 11.24
1
's cv :
0.97 a
a
i
0.90 0.70 11.30 1.01
i
a
i
1.84 1.44
1 8 5.2
LD I i df=80
a
a
e
i
df = 10 a df =9
i
8
8
8
df=99
II
1
9
75 11.56 2.08 1.58 2.10 13.08 4.10 3.61 4.80
g 156 12.63 1.68 a 2.51 1.61 15.19 3.33 1 6.12 3.92
i 299 83.42 1.14 a 3.69 1.23 1 6.872.30 i 8.23 2.76
(12/60 total Cv : 4 . 26* @ "x ==167, 2.02* @ x"=380) 1
Manufacturer's CV: I 2.5-3.1 14.6-6. 4
22
Table II. Statistical Analysis of Precision Data of Colorimetric
Procedures
Analyte 8 Mean 8 Within 8 Within BDay-to-day 8 Total
1 Cone 1 run 1 day 1 I
i s cv,*a s cv,* i s cv,* i s cv,*
48- 4--___--_-_Hh
Albumin 8 a df=80 8 df=10 8 df=9 a df=99
<g/dl) 11 j j ,
8 1.2 8 0.03 2.47 1 .003 0.26 8 0.02 1.46 8 0.04 3.02
1 2.4 8 .041 1.678 .027 1.11 8 .018 0.73 8 .051 2.11
I 4.1 I .069 1.68 8 .013 0.32 8 .050 1.22 1 .085 2.06
a i a
(12/60 total CV: 3.33* @ x=2.9, 3.01* @ 1T= 3.6)
Manufacturer's CV: 1.2-1.4 8 1.3 - 2.6 I 1.5 - 2.0 1
> -""""-u'--"---"-"--" ! 1 ,] .,ii.
Cholesterol 1 df=80 I df=10 1 df=9 1 df=99
(mg/dl) 11 1 B I
I 64 8 1.18 1.84 8 1.15 1.80 8 0.25 0.39 8 1.65 2.57
8134 1 1.72 1.298 1.13 0.848 2.03 1.528 2.82 2.11
8256 8 3.03 1.181 1.91 0.758 3.15 1.238 4.66 1.82
a a a
(12/60 total CV: 3.89* @ x"= 122, 3.81* @ x= 151)
Manufacturer's CV: 1 .24-2 .23 8 1.31-2.09 I 8 2.10 -2.41
wiir-r'ii^ir^^Mi.wiiiMiiMiiBi||iMiBMii--iiiiiiiiii-iii^iMiiiiBiiiiaiii-n"-tTTTnrT"rmffl)trir-;iiiTii-ri n ''n ,!r-,%t.-1llll ml mttmmwmnimwiiiMflnnn [MiijMiiMitM IL
Glucose 8 8 df=80 a df=10 8 df=9 1 df=99
(mg/dl) 8 8 8 8 8
1 31 8 0.53 1.76 1 0.68 2.23 8 0.36 1.19 8 0.92 3.03
8 90 8 1.67 1.851 1.18 1.318 0.86 0.961 2.19 2.43
8243 8 2.25 0.938 2.89 1.19 8 4.49 1.851 5.60 2.3
8 8 8
(6/60 total CV: 3.10 * @ x= 97, 2.24* @ x=304)
Manufacturer's CV: 8 1 1.4-4.81
_. , , -~-~. a 4 -.-^^-^^..a
Phosphorus 8 df=80 8 df = 10 8 df=9 8 df=99
(mg/dl) 8 1 8 B 8
8 1.6 8.036 2.27 I .043 2.69 1 8.049 3.11
I 3.0 8.045 1.47 8 .051 1.67 8 8.064 2.11
8 6.3 8.073 1.17 8 .091 1.45 8 .099 1.58 B . 149 2.38
8 t B
(12/60 total CV: 2.28* @ x= 3.3, 1.65* @ x= 7.1)
Manufacturer's CV: 1.2-3.7 8 I 1.1 - 2.2 8
,^.^__^___j__...^jijmmiwiiiiliiiwiumi^immiiiimiwpiiiiiwi^^'TTii iiTiTMmTMn-BiwnnffTTTTmMiwi^niMiiwiiiwiiiMiiiMiwiwiiiiwiiiiMiiiiiiiMiiiiHii itiii mi.. u *Bammmmmam&ttmmmMmami
Total protein 1 df=80 8 df=10 8 df=9 8 df=99
(g/dl) 8 8 8 1 i
1 2.4 8.048 2.00 1 .019 0.77 8 .020 0.828 .055 2.28
8 4.7 8.087 1.86 8 .026 0.56 8 .033 0.70 8 .096 2.05
8 7.8 8.109 1.39 1 .050 0.64 8 .073 0.94 B .138 1.77
8 8 8
(12/60 total CV: 2.44* "x= 4.9, 1.80* @ x=5.8)
Manufacturer's CV: 1.35 ! 8 8 1.5 - 2.7
, , _ . -*
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Table III. Statistical Analysis of Precision Data for
Triglyceride, Urine Phosphorous, and CSF total protein
Analyte BMean 8 Within i Within 8 Day-to-day 1 Total
BConc. 8 run 8 day 8 8
8 a s cv* i s cv* i s cv* a s cv*
" ' ' m| . -, a .__.--ii--.-"--- |^^. ____-.
Triglyceride 1 df=80 8 df=10 B df=9 8 df=99
(mg/dl) IB 1 8 8
8 48 82.70 5.67 S 2.49 5 . 23 8 8 3.54 7.43
8142 B3.05 2.14 1 2.98 2.09 8 2.16 1.52B 4.70 3.30
8294 85.06 1.72 I 4.57 1 . 56 8 4.13 1.411 7.82 2.66
B J fl
(ABA total CV: 1.70 * @ x= 90, 3.86 * @ x= 105)
Manufacturer's CV: 2.4-2.8 1 2.6 - 3.8 8 I 2.9 - 4.4
""" i.yi.1... ...r_l_ H-,.,.,1, i-,...-4. .iii....,im.,. - ,,-ifl.
Urine 8 I df=60 i df=10 8 df=9 B df=79
Phosphorous 8 8 B 8
mg/dl 8 5.2 B0.05 1.01 8 0.07 1.34 8 0.10 1.878 0.13 2.44
810.3 80.09 0.84 8 0.13 1.24 B 0.14 1.338 0.13 2.44
8 i 8 1 B
8 8 I
Manufacturer's CV: 1.2 - 3.7 8 11.1-2. 2 8
_ _____ ___ 8- -4 fl _,
CSF TP 8 8 df=80 8 df=10 B df=9 1 df=99
mg/dl SB I I 1
(Biuret) 8 25 83.66 14.48B 2.03 8.02 8 2.61 10.311 4.85 19.18
I 46 83.37 6.01B 8 1.73 3.808 3.70 8.12
1118 84.09 3.461 4.13 3.50 8 5.79 4.908 7.97 6.75
a a i
Manual method CV: 8* over all levels
- -? ii- a
CSF TP 8 8 df=80 8 df=10 8 df=9 8 df=99
mg/dl 8 8 1 I I
(Pierce) 8 27 83.31 12.348 2.09 7.50 8 1 3.45 12.9
8 49 82.69 5.49 8 2.99 6 . 09 B 8 3 . 72 7.58
8114 13.81 3.358 5.33 4.69 8 B 6.23 5.48
1 8 8
Manufacturer's CV: 1.6-3.0 8 3.3 - 3.5 I 3.0 fl
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2.91 *. Although the precision for CSF TP, 5.6-12.9 * over all
levels, was not quite as good as that claimed by the
manufacturer, 1.6 - 3.5*, it was an improvement over the
precision in the existing method in use, 8*. The convenience
and reproducibility of this automated method along with a
precision as acceptable as the manual method outweighed its
disadvantage of lower linearity than the biuret method.
Precision studies were done both on the Pierce Coomassie blue
and adaptation of the biuret method simultaneously to save time
since the method eventually to be adopted depended on the
outcome of the precision and accuracy studies. Past experience
with Coomassie blue protein procedures had been problematic and
the Pierce version of this reaction had to be proven reliable.
Linearity study. Linearities were determined for each
procedure by making a pool of serum or spinal fluid with high
levels of analyte which were then diluted to make
concentrations of analyte varying from 10
- 100 * of the total
concentration. These were then analyzed and the absorbance
changes (Y) were plotted against the per cent concentration on
the X axis. The delta absorbance at the point where the plot
was no longer linear was then converted to a numerical value
according to the correct algorithm for that particular method.
Patient pools rather than control material were used to
determine linearities to simulate testing conditions. Table IV
lists all the methods evaluated and the linear ranges
determined for the MCA and for comparison the limits claimed by
25
Table IV. Linearities
Analyte Upper limit
of linearity
Claimed
linearity
ABA
linearity
Alkaline
phosphatase 700 IU/L 600 IU/L 446 IU/L
ALT 360 IU/L 348 IU/L 300 IU/L
AST 700 IU/L 715 IU/L 400 IU/L
CK 1200 IU/L 1000 IU/L 1100 IU/L
GGT 660 IU/L 500 IU/L 500 IU/L
LD 800 IU/L 1900 IU/L 1000 IU/L
Albumin 6 g/dl
Cholesterol 794 mg/dl
Phosphorous 16 mg/dl
Total protein 12.5 g/dl
7 g/dl
500 mg/dl
Glucose 900 mg/dl 750 mg/dl
15 mg/dl
12 g/dl
Triglyceride 570 mg/dl 500 mg/dl
6 g/dl
550 mg/dl
700 mg/dl
15 mg/dl
12 g/dl
700 mg/dl
CSF TP,
biuret
CSF TP,
Coomassie
blue
400 mg/dl 400 mg/dl
140 mg/dl 140 mg/dl
400 mg/dl
(manual
method)
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the manufacturer. Most of the linearities met or exceeded that
of the manufacturer or the method it was designed to replace
with the exception of LD and CSF TP. LD had a much lower
linearity than theoretically claimed because it is very
temperature dependent. The manufacturer recommended running
the MCA at 30C and provided a conversion factor if the test
was done at 37C. The claimed linearity cited was calculated
from that conversion factor. In reality, at 37oC the testing
parameters had to be changed markedly to reduce sample volume
and increase reagent volume as well as changing incubation
times so that absorbance readings were taken during the linear
portion of the reaction. At 37C, the reaction was very fast
and the substrate was depleted faster than at a lower
temperature thus resulting in lower linearity. This was not
deemed a problem because only LD's that were above the
linearity level of the SMA 12/60 were run on the MCA and they
were automatically done on dilution since it was known that the
activity was elevated. CSF total protein also had a lower
linearity than the manual biuret method in use, but the ease of
testing, good precision, good accuracy and reproducibility were
advantages that outweighed the disadvantages of the lower
linearity- Also, the modified Coomassie blue reaction
equalizes the difference in reactivity of albumin and globulin
which is not true for the biuret reaction. The absorbance
changes for the biuret reaction, when automated, were ten-fold
smaller than for the Coomassie blue reaction (.002
-
.015 vs.
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.02
-
.12) which could affect the sensitivity of the test.
Last, antibiotics cause drug interferences and can falsely
elevate results in the biuret reaction. Since several drugs
can cross the blood-brain barrier in meningitis, 27 for example
Vancomycin, used to treat shunt infections, and CSF total
protein is one of the diagnostic tests used to monitor
meningitis, it was deemed important to minimize potential drug
interferences. Appendix A lists advantages and disadvantages
and drug effects for the biuret and Coomassie blue CSF TP
methods .
Interference studies. Table V summarizes the effects of
lipemia on total protein measurement by the biuret method. By
comparing the calculated expected total protein value with the
actual amount of total protein measured in increasingly more
lipemic samples, it was determined that lipemia did not affect
total protein values over the given range of linearity, 12
g/dl. Also, when a sample that was falsely elevated due to
lipemia was diluted into the range of linearity, the result
became accurate once again. Triglyceride and cholesterol
levels were also measured to see how high they would be before
they had an effect. Not until a sample measured greater than
12 g/dl, with a cholesterol of 422 mg/dl and a triglyceride of
1652 mg/dl was the total protein falsely elevated.
28
Table V- The effect of lipemia on TP analysis by
biuret
Expected Measured Visible Triglyceride
TP. ct/dl TP, q/dl lipemia
after
mq/dl
reaction
6.65 6.6 no 243
6.7 6.7 no 267
6.75 6.7 no 289
6.85 6.8 no 341
7.10 7.1 no 445
7.25 7.4 no 641
8.2 8.2 yes 1056
9.6 9.6 yes 1407
11.95 12.6 yes 1652
13.4 16.7 yes 1633
mq/dl
252
249
253
255
265
286
321
422
422
656
Diluted samples:
4.25 4.3 no 517 196
4.8 4.9 no 855 238
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Accuracy Study. Figures 6-24 represent the correlation graphs
between the MCA and the respective comparison instruments and
methods. All tests had very good correlation with minimal
random error about the mean. For the enzyme tests, the slope
of the regression equation sometimes varied markedly from one
as follows: Alkaline phosphatase with a slope of 0.7412, ALT
with a slope of 0.8112, AST with a slope of 0.6970, and GGT
with a slope of 0.7101. The slope for LD was 0.9498 and the
intercept was -44.7042. Thus, for these enzymes a correction
factor based on the regression equation was developed so that
the results from the MCA would be equivalent to those from the
12/60. The slope for CK was 0.9296 and a correction factor was
not needed since the MCA was the primary instrument for this
analysis. What was needed was an evaluation of the normal
range for CK .
Normal study. A reference range study using routine blood
donations to the American Red Cross as samples verified that
the existing ranges were valid for the MCA AST, ALT, Alkaline
phosphatase, GGT and LDH. As expected, since CK utilized a new
activated kit, a new reference range had to be established for
that enzyme. Statistical analysis of the reference range study
was done by the Strong Memorial Hospital clinical chemistry
quality control division and the decision on whether to adopt
new ranges was made by the faculty.
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Figure 6. Regression Analyis and Correlation Graph
between the SMA 12/60 and MCA for Albumin
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Figure 7. Regression Analysis and Correlation between
the SMA 12/60 and the MCA for Cholesterol
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Figure 8. Regression Analysis and Correlation between
the Ektachem 400 and MCA for Cholesterol
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Figure 9. Regression Analysis and Correlation Graph
between the ASTRA and MCA for Glucose
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Figure 10. Regression Analysis and Correlation Graph
between the Ektachem 400 and MCA for
Glucose
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Figure 11. Regression Analysis and Correlation Graph
between the SMA 12/60 and MCA for
Phosphorous
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Figure 12. Regression Analysis and Correlation Graph
between the ABA 100 and MCA for Urine
Phosphorous
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Figura 13. Regression Analysis and Correlation Graph
between the SMA 12/60 and MCA for Total
Protein
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Figure 14. Regression Analysis and Correlation Graph
between the Ektachem 400 and MCA for Total
Protein
39
<
o
2
v
\
0>
12
11
10
9
8
7
6
5
4
3
2
1
TOTAL PROTEIN
y =-0.6211 +1.1170 x
r =0.9826
n =91
s =0.2719
Y.X
0
"T
6 10 12
g/dl, Ektachem 400
Figure 15. Regression Analysis and Correlation Graph
between the ABA-100 and MCA for Fluid Total
Protein
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Figure 16. Regression Analysis and Correlation Graph
between the SMA 12/60 and MCA for Fluid
Total Protein
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Figure 17. Regression Analysis and Correlation Graph
between the manual biuret and MCA for CSF
Total Protein
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Figure 18. Regression Analysis and Correlation Graph
between the Ektachem 400 and MCA for
Triglyceride
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Figure 19. Regression Analysis and Correlation Graph
between the SMA 12/60 and MCA for Alkaline
Phosphatase
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Figure 20. Regression Analysis and Correlation Graph
between the ABA-100 and MCA for ALT
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Figure 21. Regression Analysis and Correlation Graph
between the SMA 12/60 and MCA for AST
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Figure 22. Regression Analysis and Correlation Graph
between the ABA-100 and MCA for Creatine
Kinase
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Figurer 23. Regression Analysis and Correlation Graph
between the ABA-100 and MCA for GGT
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Figure 24. Regression Analysis and Correlation Graph
between the SMA 12/60 and MCA for LD
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SUMMARY
The MCA was evaluated to replace the ABA 100 as the
primary test instrument for ALT, CK, GGT, urine phosphorous
and triglyceride, as a primary instrument for CSF total
protein, and as a backup instrument for the SMA 12/60 and
Ektachem 400. Due to the large sample volume required for
the SMA 12/60, any repeat analysis due to a channel problem
or an elevated result needed to be done on an instrument
that required small sample volumes since the amount of
sample left for analysis after SMA 12/60 testing was
completed usually was in microliters. Thus, an instrument
that could analyze alkaline phosphatase, AST, LD, TP,
albumin, cholesterol and phosphorous on small sample
volumes was needed. The patient population at Strong
Memorial Hospital is such that enough repeat testing is
necessary daily to justify the existence of a separate
instrument for such a purpose. Also, the laboratory is
often asked to do special studies for which a discrete
micro-analyzer is well suited. Although a rotor can hold
only 16 patient samples, the speed of testing and ease of
set-up made it easy and faster to do several replicate
analyses on the MCA than on other intruments. The glucose
test is used as a weekly check to test the precision of the
instrument, especially that of the loader. The Hamilton
syringes need regular bi-weekly tip re-placement. Although
glucoses were not to be done regularly on the MCA, it was
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important to make sure that they were indeed precise and
accurate since that test was used for quality control
purposes. Therefore, glucose was the first test to be
evaluated .
There were some problems with defective computer
boards when the instrument first arrived, but once they
were replaced with fully functional boards, the MCA proved
to be a reliable, fast, reproducible, accurate, and easily
operated instrument.
Even though a special methanol and water rinse of the
sample probes and tubing are required to wash out the dye
which attaches itself easily to plastic, the method
adaption that proved to be most popular among the bench
technologists was the automated CSF total protein. The
other methods benefitted only the day staff since they were
not stat tests, but CSF total protein decreased the
analysis time required by the technologist, an especially
important benefit on the evening and night shifts. Repeat
CSF TP analysis with the manual method had been laborious,
but the reliability of the Pierce method meant repeat
analysis was usually only necessary when a sample was too
high for the linearity of the method rather than a result
of a technical problem with testing.
The MCA was as precise and accurate as claimed and was
put into immediate use as soon as the evaluation period was
completed .
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APPENDIX A - Drug Interferences in CSF Total Protein
Drug Crosses Biuret Pierce
blood-brain
barrier
DuPont
aca
Chloramphenicol yes
(toxic @ 25 ug/ml)
no data none at yes
26 ug/ml
Amikacin
(peak: 25-30 ug/ml)
No data
Vancomycin yes, in No data
(peak: 25-30 meninigitis
ug/ml) used
orally and intrathecally for shunt infections
Gentamycin &
Tobramycin
(peak: 7 ug/ml)
yes, in
meningitis
No data
Methicillin No data Significant
Metrizamide Settles esp .
(CAT scan in lumbar
contrast medium) region
No data Significant
Penicillin &
Antibiotics
Denotes
drugs used
to treat
pediatric
meningitis
yes
(Urine protein
biuret methods
have been well
documented for
their incorrect
results when oral
antibiotics are
present. Since
these drugs cross
the blood-brain
barrier, esp.
during meningitis
it is likely that
falsely elevated
results can occur
Tested and
found no inter
ference from
Wycillin,
Streptomycin,
Neomycin sulfate,
Tetracycline,
& Tolbutamide.
Slight
Note: DuPont aca uses a
TCA turbidimetric CSF TP
method and used
Coomassie blue to detect
"true"
value when drug
interferences were
studied.
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